Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Next Previous
X
Search
Trial Profile

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAURA
  • Sponsors AstraZeneca

    • Most Recent Events

    • 04 Jun 2024 Results exploring if plasma ctDNA-based, tumor-informed MRD could predict disease recurrence were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 22 May 2024 According to an AstraZeneca media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
    • 20 May 2024 Planned End Date changed from 31 Dec 2030 to 31 Jan 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top